It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...